DAM
TARA icon

DLD Asset Management’s Protara Therapeutics TARA Stock Holding History

DLD Asset Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-157,349
Closed -$461K – 221
2022
Q2 		$461K Sell
157,349
-72,182
-31% -$264K 0.03% 156
2022
Q1 		$1.17M Buy
229,531
+300
+0.1% +$1.58K 0.07% 110
2021
Q4 		$1.55M Buy
+229,231
New +$1.58M 0.08% 88

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FAIM
Financial Advocates Investment Management Olympia, Washington $178M AUM 21.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DLD Asset Management's TARA Position: Q3 2022 in Review

DLD Asset Management sold out of Protara Therapeutics (TARA) in Q3 2022, closing a stake of 157,349 shares — an estimated $461K sold.

DLD Asset Management first reported a position in TARA in Q4 2021 and held it in 3 quarters. The position peaked at $1.55M in Q4 2021. 31 funds tracked by Wall St. Rank hold TARA as of Q3 2022.

  • DLD Asset Management reported no remaining Protara Therapeutics position as of Q3 2022 after selling out during the quarter.
  • DLD Asset Management sold 157,349 Protara Therapeutics shares in Q3 2022, an estimated $461K.
  • DLD Asset Management first reported a position in Protara Therapeutics in Q4 2021 and held it in 3 quarters.
  • DLD Asset Management's Protara Therapeutics position peaked at $1.55M in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2022.

Based on DLD Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.